Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type

ELGER WALTER, BEIER SYBILLE, KOSUB BEATE, FAEHNRICH MARIANNE, CHWALISZ KRZYSZTOF, HASAN SYED HAMIDUDDIN, POTTS GORDON OLIVER
1998
OA: closed Metadata only
⚙ AI-generated summary by qwen3.7-flash, 2026-09-11 ⓘ

A pharmaceutical agent combining a trilostane or epostane-type progesterone synthesis inhibitor with an antigestagen is disclosed for treating endometriosis, dysmenorrhea, and hormone-dependent tumors.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A pharmaceutical agent contains a progesterone synthesis inhibitor (ProI) of the trilostane or epostane type and an antigestagen (AG). It can be used for inducing delivery at term in humans and animals, for terminating normal or pathological pregnancies therein or for treatment of hormone-dependent tumors, endometriosis or dysmenorrhea.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-30T09:23:35.175841+00:00